Compare MDV & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | UNCY |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.6M | 126.4M |
| IPO Year | 2022 | 2021 |
| Metric | MDV | UNCY |
|---|---|---|
| Price | $14.45 | $5.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 35.1K | ★ 348.2K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | ★ 8.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,479,000.00 | N/A |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $0.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.62 | $3.71 |
| 52 Week High | $17.15 | $11.00 |
| Indicator | MDV | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 51.58 |
| Support Level | $14.23 | $5.35 |
| Resistance Level | $14.81 | $6.95 |
| Average True Range (ATR) | 0.31 | 0.35 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 25.28 | 31.97 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.